Journal of Gastrointestinal Surgery

, Volume 15, Issue 11, pp 2089–2097 | Cite as

Infiltrating Hepatocellular Carcinoma: Seeing the Tree through the Forest

  • Aram Demirjian
  • Peter Peng
  • Jean-Francois H. Geschwind
  • David Cosgrove
  • Jacob Schutz
  • Ihab R. Kamel
  • Timothy M. Pawlik
Review Article



Hepatocellular carcinoma (HCC) is a leading cause of cancer-related death worldwide. It is traditionally difficult to cure, especially when discovered at later stages, making early diagnosis and intervention of paramount importance. HCC typically arises in the background of chronic liver disease and can have various morphologic appearances. One of the most difficult of these to recognize on early surveillance imaging is the infiltrative subtype, which can account for up to 13% of all HCC cases, and may be more closely associated with background hepatitis B infection.


Certain imaging characteristics can provide vital clues, including differing signal intensity on the T1 and T2 sequences of magnetic resonance imaging (MRI) and the presence/appearance of portal vein thrombus. Owing to the diffuse and infiltrating properties of this tumor, surgical resection and transplantation are rarely if ever viable therapeutic options. Other forms of liver-directed therapy have been attempted with limited success, having minimal efficacy and high morbidity. To date, there is no data available to determine if the various HCC subtypes respond to systemic therapy differently, so this may be the most reasonable approach. Left untreated, observed patients commonly progress to hepatic failure fairly rapidly.


Infiltrative HCC can be extremely subtle, and therefore difficult to detect, especially in the background of cirrhosis. Providers caring for patients with hepatitis, chronic liver disease, and cirrhosis must be extremely vigilant in the evaluation of surveillance imaging in order to potentially discover this HCC subtype as early as possible and initiate a multidisciplinary treatment plan.


Hepatocellular Infiltrating Imaging Prognosis Management 


  1. 1.
    Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55(2):74–108.PubMedCrossRefGoogle Scholar
  2. 2.
    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003; 362(9399):1907–17.PubMedCrossRefGoogle Scholar
  3. 3.
    Cunningham SC, Tsai S, Marques HP, et al. Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Ann Surg Oncol 2009; 16(7):1820–31.PubMedCrossRefGoogle Scholar
  4. 4.
    Huang J, Yan L, Cheng Z, et al. A randomized trial comparing radiofrequency ablation and surgical resection for HCC conforming to the Milan criteria. Ann Surg; 252(6):903–12.Google Scholar
  5. 5.
    Okuda K, Noguchi T, Kubo Y, et al. A clinical and pathological study of diffuse type hepatocellular carcinoma. Liver 1981; 1(4):280–9.PubMedGoogle Scholar
  6. 6.
    Trevisani F, Caraceni P, Bernardi M, et al. Gross pathologic types of hepatocellular carcinoma in Italian patients. Relationship with demographic, environmental, and clinical factors. Cancer 1993; 72(5):1557–63.PubMedCrossRefGoogle Scholar
  7. 7.
    Kanematsu M, Semelka RC, Leonardou P, et al. Hepatocellular carcinoma of diffuse type: MR imaging findings and clinical manifestations. J Magn Reson Imaging 2003; 18(2):189–95.PubMedCrossRefGoogle Scholar
  8. 8.
    Chemin I, Zoulim F. Hepatitis B virus induced hepatocellular carcinoma. Cancer Lett 2009; 286(1):52–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Brechot C. Pathogenesis of hepatitis B virus-related hepatocellular carcinoma: old and new paradigms. Gastroenterology 2004; 127(5 Suppl 1):S56–61.PubMedCrossRefGoogle Scholar
  10. 10.
    Wang XW, Forrester K, Yeh H, et al. Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. Proc Natl Acad Sci U S A 1994; 91(6):2230–4.PubMedCrossRefGoogle Scholar
  11. 11.
    Shiratori Y, Shiina S, Imamura M, et al. Characteristic difference of hepatocellular carcinoma between hepatitis B- and C-viral infection in Japan. Hepatology 1995; 22(4 Pt 1):1027–33.PubMedCrossRefGoogle Scholar
  12. 12.
    Castells L, Vargas V, Gonzalez A, et al. Long interval between HCV infection and development of hepatocellular carcinoma. Liver 1995; 15(3):159–63.PubMedGoogle Scholar
  13. 13.
    Vauthey JN, Walsh GL, Vlastos G, Lauwers GY. Importance of field cancerisation in clinical oncology. Lancet Oncol 2000; 1(1):15–6.PubMedCrossRefGoogle Scholar
  14. 14.
    Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006; 25(27):3834–47.PubMedCrossRefGoogle Scholar
  15. 15.
    Benvegnu L, Noventa F, Bernardinello E, et al. Evidence for an association between the aetiology of cirrhosis and pattern of hepatocellular carcinoma development. Gut 2001; 48(1):110–5.PubMedCrossRefGoogle Scholar
  16. 16.
    Myung SJ, Yoon JH, Kim KM, et al. Diffuse infiltrative hepatocellular carcinomas in a hepatitis B-endemic area: diagnostic and therapeutic impediments. Hepatogastroenterology 2006; 53(68):266–70.PubMedGoogle Scholar
  17. 17.
    Farinati F, Marino D, De Giorgio M, et al. Diagnostic and prognostic role of alpha-fetoprotein in hepatocellular carcinoma: both or neither? Am J Gastroenterol 2006; 101(3):524–32.PubMedCrossRefGoogle Scholar
  18. 18.
    Malaguarnera G, Giordano M, Paladina I, et al. Serum markers of hepatocellular carcinoma. Dig Dis Sci; 55(10):2744–55.Google Scholar
  19. 19.
    Miyaaki H, Nakashima O, Kurogi M, et al. Lens culinaris agglutinin-reactive alpha-fetoprotein and protein induced by vitamin K absence II are potential indicators of a poor prognosis: a histopathological study of surgically resected hepatocellular carcinoma. J Gastroenterol 2007; 42(12):962–8.PubMedCrossRefGoogle Scholar
  20. 20.
    Taketa K. Alpha-fetoprotein: reevaluation in hepatology. Hepatology 1990; 12(6):1420–32.PubMedCrossRefGoogle Scholar
  21. 21.
    Tada T, Kumada T, Toyoda H, et al. Relationship between Lens culinaris agglutinin-reactive alpha-fetoprotein and pathologic features of hepatocellular carcinoma. Liver Int 2005; 25(4):848–53.PubMedCrossRefGoogle Scholar
  22. 22.
    Okuda H, Nakanishi T, Takatsu K, et al. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone. J Gastroenterol Hepatol 2002; 17(7):772–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Sherman M. The radiological diagnosis of hepatocellular carcinoma. Am J Gastroenterol; 105(3):610–2.Google Scholar
  24. 24.
    Baron RL, Brancatelli G. Computed tomographic imaging of hepatocellular carcinoma. Gastroenterology 2004; 127(5 Suppl 1):S133–43.PubMedCrossRefGoogle Scholar
  25. 25.
    de Ledinghen V, Laharie D, Lecesne R, et al. Detection of nodules in liver cirrhosis: spiral computed tomography or magnetic resonance imaging? A prospective study of 88 nodules in 34 patients. Eur J Gastroenterol Hepatol 2002; 14(2):159–65.PubMedCrossRefGoogle Scholar
  26. 26.
    Willatt JM, Hussain HK, Adusumilli S, Marrero JA. MR Imaging of hepatocellular carcinoma in the cirrhotic liver: challenges and controversies. Radiology 2008; 247(2):311–30.PubMedCrossRefGoogle Scholar
  27. 27.
    Burrel M, Llovet JM, Ayuso C, et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 2003; 38(4):1034–42.PubMedGoogle Scholar
  28. 28.
    Noguchi Y, Murakami T, Kim T, et al. Detection of hepatocellular carcinoma: comparison of dynamic MR imaging with dynamic double arterial phase helical CT. AJR Am J Roentgenol 2003; 180(2):455–60.PubMedGoogle Scholar
  29. 29.
    Kim YK, Han YM, Kim CS. Comparison of diffuse hepatocellular carcinoma and intrahepatic cholangiocarcinoma using sequentially acquired gadolinium-enhanced and Resovist-enhanced MRI. Eur J Radiol 2009; 70(1):94–100.PubMedCrossRefGoogle Scholar
  30. 30.
    Catalano OA, Choy G, Zhu A, et al. Differentiation of malignant thrombus from bland thrombus of the portal vein in patients with hepatocellular carcinoma: application of diffusion-weighted MR imaging. Radiology; 254(1):154–62.Google Scholar
  31. 31.
    Pawlik TM, Poon RT, Abdalla EK, et al. Critical appraisal of the clinical and pathologic predictors of survival after resection of large hepatocellular carcinoma. Arch Surg 2005; 140(5):450–7; discussion 57–8PubMedCrossRefGoogle Scholar
  32. 32.
    Pawlik TM, Poon RT, Abdalla EK, et al. Hepatectomy for hepatocellular carcinoma with major portal or hepatic vein invasion: results of a multicenter study. Surgery 2005; 137(4):403–10.PubMedCrossRefGoogle Scholar
  33. 33.
    Han YS, Choi DL, Park JB. Cirrhotomimetic type hepatocellular carcinoma diagnosed after liver transplantation—eighteen months of follow-up: a case report. Transplant Proc 2008; 40(8):2835–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Ochiai T, Sonoyama T, Ichikawa D, et al. Poor prognostic factors of hepatectomy in patients with resectable small hepatocellular carcinoma and cirrhosis. J Cancer Res Clin Oncol 2004; 130(4):197–202.PubMedCrossRefGoogle Scholar
  35. 35.
    Lencioni R. Loco-regional treatment of hepatocellular carcinoma. Hepatology; 52(2):762–73.Google Scholar
  36. 36.
    Lo CM, Ngan H, Tso WK, et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35(5):1164–71.PubMedCrossRefGoogle Scholar
  37. 37.
    Llovet JM, Real MI, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359(9319):1734–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Lopez RR, Jr., Pan SH, Hoffman AL, et al. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma. Arch Surg 2002; 137(6):653–7; discussion 57–8PubMedCrossRefGoogle Scholar
  39. 39.
    Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359(4):378–90.PubMedCrossRefGoogle Scholar

Copyright information

© The Society for Surgery of the Alimentary Tract 2011

Authors and Affiliations

  • Aram Demirjian
    • 1
  • Peter Peng
    • 1
  • Jean-Francois H. Geschwind
    • 2
  • David Cosgrove
    • 3
  • Jacob Schutz
    • 4
  • Ihab R. Kamel
    • 4
  • Timothy M. Pawlik
    • 1
  1. 1.Department of SurgeryThe Johns Hopkins University School of MedicineBaltimoreUSA
  2. 2.Department of Interventional RadiologyThe Johns Hopkins University School of MedicineBaltimoreUSA
  3. 3.Department of Medical OncologyThe Johns Hopkins University School of MedicineBaltimoreUSA
  4. 4.Department of RadiologyThe Johns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations